Brehler R, Bergholz M, Rauschecker H, Blossey H C, Schauer A
Klin Wochenschr. 1986 Apr 15;64(8):370-4. doi: 10.1007/BF01728186.
Immunohistochemical examinations of 89 breast cancer specimens were performed using two different monoclonal antibodies. One marked the nuclear estrogen-receptor (ER) protein (anti-ER, Abbott), whereas the other marked an ER-related cytoplasmic protein (ER-D5 Amersham). Comparison of the results of the biochemical assay with those of the immunohistochemical markers revealed the following correlations: 75% anti ER and 71% ER-D5. Clinical follow-up studies are necessary to specify the relevance of these new immunohistochemical techniques in the anti-hormonal therapeutic management of breast cancer patients.
使用两种不同的单克隆抗体对89份乳腺癌标本进行了免疫组织化学检查。一种标记核雌激素受体（ER）蛋白（抗ER，雅培公司），而另一种标记一种与ER相关的细胞质蛋白（ER-D5，安玛西亚公司）。生化检测结果与免疫组化标记结果的比较显示了以下相关性：抗ER为75%，ER-D5为71%。有必要进行临床随访研究，以明确这些新的免疫组化技术在乳腺癌患者抗激素治疗管理中的相关性。
